Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
Frontiers of Radioimmunotherapy
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Frontiers of Radioimmunotherapy

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Biochemistry".

Deadline for manuscript submissions: closed (12 December 2014) | Viewed by 17342

Special Issue Editors

Dr. Rune Nilsson

E-Mail Website
Guest Editor
Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden
Interests: radioimmunotherapy; tumor immunology, immunotherapy; tumor microenvironment; antibody conjugates
Dr. Sophie E. Eriksson

E-Mail Website
Guest Editor
Lund University Cancer Center (LUCC), Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden
Interests: radioimmunotherapy; radionuclides; metastases; radiobiology; preclinical models

Special Issue Information

Dear Colleagues,

Radioimmunotherapy, which utilizes radiolabeled antibodies for targeting tumors, is now an established therapy for Non-Hodgkin lymphoma (NHL) patients. Clinical research is still on-going to further improve the therapy for these patients (e.g., by attempting to prolong the duration of the clinical response).

The majority of the current pre-clinical radioimmunotherapy research aims at transferring the clinical success of treating lymphoma to treating solid tumors. Solid tumors are generally more radioresistant than NHL and require higher absorbed doses for therapeutic effect. Poor tumor accretion and the unfavorable pharmacokinetics of radiolabeled antibodies are major impediments that limit the efficacy of radioimmunotherapy in solid tumors. Ways of increasing the therapeutic outcome may involve pretargeting (where an unlabeled antibody construct is followed by a radiolabeled low molecular weight component that binds to the antibody construct), fractionated radioimmunotherapy, and the use of alpha-particle emitting radionuclides that have a higher radiobiological effect than that of the generally used beta-particle emitters. Radioimmunotherapy with alpha-particle emitters has been proposed for treating disseminated or residual diseases (due the short range of the particles).

Clinically, the consensus is that radioimmunotherapy is best used to treat small tumors (instead of bulky diseases). An interesting area for clinical research is the evaluation of combining radioimmunotherapy with other modalities (e.g. chemotherapy, tyrosine kinase inhibitors or immunotherapy).

The articles in this Special Issue of IJMS will cover a broad range of topics, from both pre-clinical and clinical research, which concern the improvement of radioimmunotherapy, so as to give the reader an update on the latest developments.

Dr. Rune Nilsson
Dr. Sophie E. Eriksson
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


Keywords

  • radioimmunotherapy
  • radionuclide therapy
  • radionuclide
  • alpha emitter
  • beta emitter
  • pretargeting
  • tumor therapy
  • radiobiology

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

829 KiB  
Review
Tumor Immunotargeting Using Innovative Radionuclides
by Françoise Kraeber-Bodéré, Caroline Rousseau, Caroline Bodet-Milin, Cédric Mathieu, François Guérard, Eric Frampas, Thomas Carlier, Nicolas Chouin, Ferid Haddad, Jean-François Chatal, Alain Faivre-Chauvet, Michel Chérel and Jacques Barbet
Int. J. Mol. Sci. 2015, 16(2), 3932-3954; https://doi.org/10.3390/ijms16023932 - 11 Feb 2015
Cited by 43 | Viewed by 9063
Abstract
This paper reviews some aspects and recent developments in the use of antibodies to target radionuclides for tumor imaging and therapy. While radiolabeled antibodies have been considered for many years in this context, only a few have reached the level of routine clinical [...] Read more.
This paper reviews some aspects and recent developments in the use of antibodies to target radionuclides for tumor imaging and therapy. While radiolabeled antibodies have been considered for many years in this context, only a few have reached the level of routine clinical use. However, alternative radionuclides, with more appropriate physical properties, such as lutetium-177 or copper-67, as well as alpha-emitting radionuclides, including astatine-211, bismuth-213, actinium-225, and others are currently reviving hopes in cancer treatments, both in hematological diseases and solid tumors. At the same time, PET imaging, with short-lived radionuclides, such as gallium-68, fluorine-18 or copper-64, or long half-life ones, particularly iodine-124 and zirconium-89 now offers new perspectives in immuno-specific phenotype tumor imaging. New antibody analogues and pretargeting strategies have also considerably improved the performances of tumor immunotargeting and completely renewed the interest in these approaches for imaging and therapy by providing theranostics, companion diagnostics and news tools to make personalized medicine a reality. Full article
(This article belongs to the Special Issue Frontiers of Radioimmunotherapy)
►▼ Show Figures

Figure 1

1063 KiB  
Review
Rescue Effects: Irradiated Cells Helped by Unirradiated Bystander Cells
by R. K. K. Lam, Y. K. Fung, W. Han and K. N. Yu
Int. J. Mol. Sci. 2015, 16(2), 2591-2609; https://doi.org/10.3390/ijms16022591 - 23 Jan 2015
Cited by 34 | Viewed by 7803
Abstract
The rescue effect describes the phenomenon where irradiated cells or organisms derive benefits from the feedback signals sent from the bystander unirradiated cells or organisms. An example of the benefit is the mitigation of radiation-induced DNA damages in the irradiated cells. The rescue [...] Read more.
The rescue effect describes the phenomenon where irradiated cells or organisms derive benefits from the feedback signals sent from the bystander unirradiated cells or organisms. An example of the benefit is the mitigation of radiation-induced DNA damages in the irradiated cells. The rescue effect can compromise the efficacy of radioimmunotherapy (RIT) (and actually all radiotherapy). In this paper, the discovery and subsequent confirmation studies on the rescue effect were reviewed. The mechanisms and the chemical messengers responsible for the rescue effect studied to date were summarized. The rescue effect between irradiated and bystander unirradiated zebrafish embryos in vivo sharing the same medium was also described. In the discussion section, the mechanism proposed for the rescue effect involving activation of the nuclear factor κB (NF-κB) pathway was scrutinized. This mechanism could explain the promotion of cellular survival and correct repair of DNA damage, dependence on cyclic adenosine monophosphate (cAMP) and modulation of intracellular reactive oxygen species (ROS) level in irradiated cells. Exploitation of the NF-κB pathway to improve the effectiveness of RIT was proposed. Finally, the possibility of using zebrafish embryos as the model to study the efficacy of RIT in treating solid tumors was also discussed. Full article
(This article belongs to the Special Issue Frontiers of Radioimmunotherapy)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop